Locations:

Tag: ASCO23

23-CNR-3898261-CQD-Hero-650×450 Dr Gupta

July 10, 2023/Cancer/Research

Enfortumab Plus Pembrolizumab May Represent New First-Line Standard in Advanced Urothelial Cancer

Potential treatment option for patients who are ineligible for cisplatin

23-CNR-3898264-CQD-Hero-650×450 Stevenson

June 15, 2023/Cancer/Research

Population-Based Analysis Highlights Disparities in Lung Cancer Mortality in U.S.

Targeted interventions may prove beneficial for vulnerable subgroups, researchers suggest

June 13, 2023/Cancer/Research

Luspatercept Shows Promise as Treatment for Anemia in Patients With Myelofibrosis

Approach resulted in transfusion independence and durable anemia response

23-CNR-3898262-CQD-Hero-650×450 Yilmaz ASCO 2023

June 7, 2023/Cancer/Research

First-in-Class Bifunctional EGFR Inhibitor Shows Promising Activity in Metastatic Head and Neck Cancers, Especially When Given with Immunotherapy

Combination therapy demonstrates effectiveness in first-line treatment setting

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

June 5, 2023/Cancer/Research

Foundational Research Yields Clues to Understanding Early-Onset Colorectal Cancer

Unique molecular features found in young-onset disease

June 2, 2023/Cancer/News & Insight

Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

BackPage 1 of 1Next